Top Searches
September 10, 2010
| eCliniqua > Trial Designs



Industry Trends

Loading...

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More
Add to Del.icio.us Add to digg Add to Connotea Add to Facebook Add to LinkedIn
EMail Page
Printer Friendly
Book Mark
Reprint Rights
Trial Design

Loading...

Change page: < >  |  Displaying page 1 of 3, items 1 to 10 of 28.

Orphan Drug Research Suddenly in Vogue: Aug 16 Orphan Drug Research Suddenly in Vogue: Aug 16

DIA: Innovation, Issues-Driven, Upbeat DIA: Innovation, Issues-Driven, Upbeat

Most Approved Drugs Tested Overseas

Jun 23 | New York Times | The inspector general of the HHS released a report stating that 80% of the drugs approved for sale in 2008 had trials in foreign countries and 78% of all subjects that participated in clinical trials were enrolled at foreign sites.

Early Trial Planning Solutions & DIA News: Jun 21 Early Trial Planning Solutions & DIA News

A Social Approach to Patient Recruitment A Social Approach to Patient Recruitment

Choosing Countries for Oncology Trials

Jun 3 | News Brief | Premier Research Group has released a white paper that reviews a funnel-approach to selecting target countries for oncology trials

FDA's New PRO Guidance Highlights Patient's Perspective: May 17 FDA’s New PRO Guidance Highlights Patient’s Perspective: May 17

Integrating InForm EDC at Dana-Farber Cancer Institute Integrating InForm EDC at Dana-Farber Cancer Institute

BioClinica Acquires Cephalon's U.S. Data Management Team BioClinica Acquires Cephalon’s U.S. Data Management Team

Mayo Clinic Backs First Independent Clinical Trials: Apr 5 Mayo Clinic Backs First Independent Clinical Trials

White Papers & Special Reports

sas_f0910
Rethinking Clinical Trials Data Integration
Sponsored by SAS

There is a gap between the need for data integration and fully integrated systems. To find out why, SAS and Pharmaceutical Executive conducted confidential telephone interviews with senior pharmaceutical executives and CROs. This article discusses recommendations on how to achieve optimal clinical data integration, based on those interviews.

Download Now


ClearTrial_BriefingOn
eClinical Trial Technologies Revolutionizing Clinical Development Efficiency
Sponsored by ClearTrial
This Bio-IT World BriefingON report, sponsored by ClearTrial, presents a selection of recent stories from Bio•IT World and sister publication, eCliniqua, that illustrate how new technologies and approaches can have a profound impact on the management and execution of clinical trials.
Download Now


oracle_RDC
Remote Data Capture:Acquisition and Analysis
Sponsored by Oracle

See why Electronic Data Capture (EDC) is gaining traction in the pharmaceutical
clinical trials arena. Today approximately half of all clinical trials are conducted
electronically, and the figure is rapidly rising. Report includes contributions from
Oracle Health Sciences, Pfizer, PPD, and C3i.

 

Download Now
More White Papers & Special Reports
Life Science Webcasts & Podcasts

Bio-IT World & CHI

Impact of the 1000 Genomes Project on the Next Wave of Pharmacogenomic Discovery
1000genomeInterview with M. Eileen Dolan, Ph.D., Professor, Medicine, University of Chicago and Speaker at Next-Generation Sequencing Data Management, September 27-29, 2010, Providence, RI  

The 1000 Genomes Project aims to provide detailed genetic variation data on >1000 genomes from worldwide populations using the next-generation sequencing technologies. Some of the samples utilized for the 1000 Genomes Project are the International Hap-Map samples that are composed of lymphoblastoid cell lines (LCLs) derived from individuals of different world populations. The detailed map of human genetic variation promised by the 1000 Genomes project will allow a more in-depth analysis of the contribution of genetic variation to drug response. Future studies utilizing this new resource can greatly enhance our understanding of the genetic basis of drug response and other complex traits.


Download Now 

More Podcasts

Job Openings

mskc logo
Software Engineer – Computational Biology Center

Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.

Apply: www.mskcciscareers.org.  Equal opportunity and affirmative action employer.

Sponsored Links


Loading...

For reprints and/or copyright permission, please contact The YGS Group, 3650 West Market Street, York, PA;

(717) 505-9701 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.

Cambridge Healthtech Institute

Footer Image
Loading...
  • 250 First Avenue, Suite 300
  • Needham MA 02494
  • phone: 781-972-5400
  • fax: 781-972-5425
  • chi@healthtech.com